KONEXBiotech & Pharma233250

Median Diagnostics

₩4,900 0.00%2026-10-02 close

Market Cap

₩8.6B

Turnover

₩55,850

Volume

12 shares

Shares out.

1.8M

PER

—

PBR

—

EPS

—

Dividend Yield

0.00%

PER, PBR and dividend yield are calculated from the latest confirmed results (EPS, BPS, dividend per share) and the current share price · Prices as of the 2026-10-02 close

Report overview

Domestic Leader in Outbreak Diagnostics, Now Testing Export Breakout

As Korea's pioneering veterinary IVD company, Median Diagnostics is leveraging its GMP certification and WOAH-recognized kits to break into overseas markets, yet it continues to navigate a difficult post-COVID revenue normalization.

1
Korea's first licensed animal diagnostic manufacturer (2001), maintaining a pioneering IVD position in veterinary diagnostics
2
In May 2024, became Korea's first company to obtain GMP certification for animal IVD devices (ASF-related product groups), unlocking export eligibility for markets like China
3
The FMD rapid antigen differentiation kit, co-developed with APQA, was the sole WOAH-recognized FMD diagnostic kit as of 2023, currently exported to 15 countries including France and Saudi Arabia
4
FY2023 consolidated revenue fell 52.1% YoY with a swing to both operating and net losses, reflecting the complete dissipation of COVID-19 kit demand
5
Portfolio expansion continues with new product approvals such as the PPRV molecular diagnostic kit (2025), alongside ongoing development of human diagnostic raw material business

Business structure

Median Diagnostics operates across two core segments: (1) in-vitro diagnostic kits for animal diseases and (2) raw materials for human disease diagnostics.

The animal diagnostics segment constitutes the vast majority of revenues, with a broad product lineup spanning FMD, ASF, HPAI, CSF, Newcastle disease, bovine tuberculosis, circovirus (PCV), PED, and BVD.

Products are offered across three diagnostic platforms—rapid field kits, immunoassays (ELISA), and real-time gene diagnostics (qRT-PCR)—providing a complete diagnostic solution across detection stages.

Manufacturing is based at the Chuncheon, Gangwon-do headquarters, with a U.S. subsidiary (est. 2015) and a Seoul office supporting international business.

Core competencies lie in the company's proprietary R&D capabilities: recombinant antigen and monoclonal antibody development, CDR-sequencing-based antibody engineering, and PCR diagnostic technology.

The most direct listed competitor is Bionote (KOSDAQ: 377740), which holds a more established export network spanning 80 countries; Median Diagnostics differentiates through deep collaboration with public veterinary agencies and certifications such as WOAH recognition.

The human diagnostic raw material segment is currently progressing through ISO13485 and GMP implementation ahead of commercialization.

Recent trends

Based on disclosed financial data, FY2023 (December fiscal year-end) consolidated revenue declined 52.1% year-on-year, with both operating income and net income turning to losses.

The primary driver was the complete disappearance of COVID-19 IVD kit demand following the transition to an endemic phase, which had temporarily inflated revenues in 2022.

While the core animal diagnostics business base remains intact, the absolute revenue scale—absent the COVID windfall—is small, implying elevated fixed-cost pressure.

In terms of share price, data from around October 2025 shows the stock trading at approximately 13,190 KRW with a 52-week range of 10,190–18,500 KRW; by the June 2026 reference date, the price has retreated to 8,200 KRW, near the lower end of its recent range.

Operationally, 2024 was marked by several positive milestones: attainment of the industry's first GMP certification for animal IVD devices (May), recognition with a Ministry of Agriculture, Food and Rural Affairs Minister's Award for lumpy skin disease prevention (June), and designation as a top self-inspection company for animal pharmaceuticals (announced January 2025).

Export momentum in FMD kits—maintained to 15 countries—continues, while the company actively pursues China market entry. CEO Oh Jin-sik publicly identified human diagnostics and export markets as new growth pillars in his 2025 new-year interview.

Outlook

The South Korean government's roadmap for the animal pharmaceutical industry targets tripling the domestic market size and quintupling export volume by 2035, creating a supportive policy backdrop for IVD specialists like Median Diagnostics.

The global animal pharmaceutical market is projected to grow at approximately 8% CAGR from around KRW 61 trillion in 2022 to KRW 129 trillion by 2032, underpinning long-term demand.

The GMP certification covering ASF-related product groups is potentially a decisive entry point for the Chinese market, which requires GMP documentation on imported animal IVD products. Continuous product additions—most recently the PPRV molecular diagnostic kit—are gradually broadening the portfolio.

Near-term, the pace of post-COVID revenue recovery remains uncertain, and a delay in securing large export contracts could defer meaningful margin improvement. The timeline for completing ISO13485 and GMP infrastructure for the human diagnostics raw material business will be key to evaluating revenue diversification.

Bull factors

WOAH Recognition + GMP Certification Opening Export Channels

Median Diagnostics became Korea's first company to receive GMP certification for animal IVD devices in May 2024, while its FMD rapid antigen differentiation kit holds the distinction of being the sole WOAH-recognized diagnostic kit as of 2023, already exported to 15 countries.

GMP certification removes the institutional barrier to entering markets—most notably China—that require GMP compliance as a condition of import. Should the company extend GMP certification beyond the current ASF product groups, the addressable export market would expand meaningfully.

Go-To Partner for High-Consequence Disease Diagnostics

Since its founding in 1999, Median Diagnostics has maintained a consistent track record as Korea's first-mover in veterinary diagnostic licensing (2001), pioneering commercial diagnostic kits for ASF, FMD, and HPAI.

Its ongoing joint research relationship with the Animal and Plant Quarantine Agency (APQA) provides a structural advantage in being first-to-market with diagnostic solutions when new disease outbreaks emerge.

Government recognition—including a Minister's Award for lumpy skin disease prevention in 2024 and top-rated self-inspection company status—reinforces public sector credibility.

Broad Multi-Disease Platform and Total Diagnostic Solution

The company offers a total solution spanning a wide range of diseases—ASF, FMD, HPAI, CSF, Newcastle disease, bovine tuberculosis, PCV, PED, BVD, and PPRV—across three diagnostic platforms: rapid kits, ELISA, and qRT-PCR.

For individual diseases, the multi-tier approach (field rapid test, antibody screening, molecular confirmation) raises customer switching costs and deepens account relationships. Ongoing expansion into human diagnostic raw materials represents a medium-term diversification option that could broaden the revenue mix.

Bear factors

Steep Revenue Cliff Post-COVID Windfall

The 52.1% YoY revenue collapse in FY2023, accompanied by a swing to both operating and net losses, underscores the degree to which the company had relied on the COVID-19 diagnostic kit windfall.

The relatively small absolute scale of the core animal diagnostics business creates adverse operating leverage when revenues decline, and a slower-than-expected recovery in 2024–2025 could accelerate cash burn.

Profitability normalization is contingent on securing material export contracts or commercializing new products.

Structural Liquidity Constraints as a KONEX-Listed Stock

KONEX imposes eligibility restrictions on retail investors and structurally depresses trading liquidity versus KOSPI/KOSDAQ. The reference date data shows zero daily trading volume, which weakens price discovery and elevates liquidity risk for position exits.

Without confirmed plans or eligibility for a transfer listing to KOSDAQ, investors face meaningful constraints on exiting positions at desired prices.

Scale and Export Network Gap vs. Larger Competitors

Direct domestic competitor Bionote (KOSDAQ: 377740) commands an overwhelming distribution advantage—80-country export reach, 120 dealer and direct-sales outlets, and animal diagnostics revenue of KRW 66.4 billion in 2024.

Median Diagnostics is at a clear disadvantage in scale and global sales force, which can translate into weaker reference accounts and pricing power when competing for large overseas contracts. Whether the company can secure partnerships with global animal health majors will be a critical determinant of export scale-up.

Risk factors

Disease Outbreak Dependency

Demand for veterinary diagnostic kits is inherently tied to the incidence of livestock disease outbreaks—if major diseases are eradicated or frequency declines, associated kit demand falls in tandem. This variable demand pattern makes stable revenue forecasting challenging.

Conversely, new disease emergence creates episodic revenue spikes, but these are event-driven rather than structural growth drivers.

Overseas Regulatory and Approval Risk

Key target export markets such as China typically require local product registration and approval processes beyond GMP certification, meaning GMP attainment does not automatically translate into immediate export commencement.

Regulatory review delays or changes in standards could significantly push back the timeline for export revenue generation. The North American market, accessed via the U.S. subsidiary, also requires careful navigation of FDA-related regulatory requirements and local competitive dynamics.

Financing and Balance Sheet Risk

Following the 2023 swing to losses, cash generation has weakened while multiple capital needs—R&D investment, human diagnostics GMP infrastructure, and overseas sales expansion—compete simultaneously.

The thin liquidity of KONEX also constrains equity-based capital raising, meaning balance sheet deterioration could force a deceleration in growth investment. Any financing through convertible bonds (CBs) or equity issuance carries dilution risk for existing shareholders.

Overall view

Median Diagnostics possesses rare and defensible assets: a 25-year pioneering track record in Korean veterinary IVD, deep public veterinary agency relationships, and proprietary certifications including WOAH recognition and Korea's first GMP certification for animal IVD devices.

The government's ambitious export expansion roadmap and an estimated 8% CAGR for the global animal pharma market provide a favorable structural backdrop.

However, the FY2023 consolidated revenue collapse of 52.1% and swing to losses highlight that the core business—absent COVID windfalls—currently lacks sufficient scale to ensure profitability. Material time uncertainty remains until large overseas contracts are actually signed and revenue flows.

KONEX-inherent trading illiquidity adds a further structural constraint for investors. The current share price of KRW 8,200, representing a 55%+ decline from the 2025 high of KRW 18,500, leaves considerable room for movement in either direction depending on export execution.

On balance, a Neutral stance is appropriate, with positive revision dependent on tangible evidence of overseas sales ramp-up.

Sources

Korea Exchange (KRX) — Prices · Market Cap · Volume
FSS electronic disclosure system (DART) — Financial statements · Dividend filings

Show 8 more articles and sources

Report written 2026-06-08 · Data as of 2026-06-05

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.